These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26042859)

  • 1. Public funding of clinical-stage antibiotic development in the United States and European Union.
    Eichberg MJ
    Health Secur; 2015; 13(3):156-65. PubMed ID: 26042859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: a systematic observational analysis.
    Kelly R; Zoubiane G; Walsh D; Ward R; Goossens H
    Lancet Infect Dis; 2016 Apr; 16(4):431-40. PubMed ID: 26708524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Establishing ophthalmology in the research framework programs of the European Union].
    Scholl HP; Wheeler-Schilling TH; Zrenner E; Holz FG
    Ophthalmologe; 2006 Feb; 103(2):91-9. PubMed ID: 16437232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UK and European Union public and charitable funding from 2008 to 2013 for bacteriology and antibiotic research in the UK: an observational study.
    Bragginton EC; Piddock LJ
    Lancet Infect Dis; 2014 Sep; 14(9):857-68. PubMed ID: 25065509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
    Simpkin VL; Renwick MJ; Kelly R; Mossialos E
    J Antibiot (Tokyo); 2017 Dec; 70(12):1087-1096. PubMed ID: 29089600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Report calls for $2bn global fund to kickstart antibiotic development.
    Wise J
    BMJ; 2015 May; 350():h2635. PubMed ID: 25975228
    [No Abstract]   [Full Text] [Related]  

  • 7. The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance.
    Kostyanev T; Bonten MJ; O'Brien S; Steel H; Ross S; François B; Tacconelli E; Winterhalter M; Stavenger RA; Karlén A; Harbarth S; Hackett J; Jafri HS; Vuong C; MacGowan A; Witschi A; Angyalosi G; Elborn JS; deWinter R; Goossens H
    J Antimicrob Chemother; 2016 Feb; 71(2):290-5. PubMed ID: 26568581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy.
    Outterson K; McDonnell A
    Health Aff (Millwood); 2016 May; 35(5):784-90. PubMed ID: 27140983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomedical research. Panel votes to end prevention fund, cut economics studies, freeze NIH.
    Kaiser J
    Science; 2012 Jul; 337(6093):399. PubMed ID: 22837500
    [No Abstract]   [Full Text] [Related]  

  • 10. Medical countermeasures for national security: a new government role in the pharmaceuticalization of society.
    Elbe S; Roemer-Mahler A; Long C
    Soc Sci Med; 2015 Apr; 131():263-71. PubMed ID: 24815579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges to pharmaceutical policymaking: lessons from Australia's national medicines policy.
    Lipworth W; Doran E; Kerridge I; Day R
    Aust Health Rev; 2014 May; 38(2):160-8. PubMed ID: 24589424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ABCs of the US Broad Spectrum Antimicrobials Program: Antibiotics, Biosecurity, and Congress.
    Billington JK
    Health Secur; 2015; 13(6):349-54. PubMed ID: 26569379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Federal funding in support of Ebola medical countermeasures R&D.
    Boddie C
    Health Secur; 2015; 13(1):3-8. PubMed ID: 25812423
    [No Abstract]   [Full Text] [Related]  

  • 14. A survey of public funding of cancer research in the European union.
    Eckhouse S; Sullivan R
    PLoS Med; 2006 Jul; 3(7):e267. PubMed ID: 16842021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seeking innovation: incentive funding for biodefense biotechs.
    Nolan JM; Samad EU; Jindra LF; Brozak SG
    Biosecur Bioterror; 2010 Dec; 8(4):365-72. PubMed ID: 21142763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research priorities. Farm animal research in crisis.
    Roberts RM; Smith GW; Bazer FW; Cibelli J; Seidel GE; Bauman DE; Reynolds LP; Ireland JJ
    Science; 2009 Apr; 324(5926):468-9. PubMed ID: 19390030
    [No Abstract]   [Full Text] [Related]  

  • 17. 21st century cures: is US medicines bill a colossal mistake?
    Doshi P
    BMJ; 2015 Jul; 351():h4013. PubMed ID: 26205953
    [No Abstract]   [Full Text] [Related]  

  • 18. The European surveillance activities EARSS and ESAC in the context of ABS International.
    Metz-Gercek S; Mittermayer H
    Wien Klin Wochenschr; 2008; 120(9-10):264-7. PubMed ID: 18545949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN; Williams CS; Arrowsmith JE
    Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the Obstacles to Implementing Economic Mechanisms to Stimulate Antibiotic Research and Development: A Multi-Actor and System-Level Analysis.
    Baraldi E; Ciabuschi F; Leach R; Morel CM; Waluszewski A
    Am J Law Med; 2016 May; 42(2-3):451-486. PubMed ID: 29086643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.